Summary
CME Group Inc. (CME) filed an 8-K on May 19, 2026, reporting on its 2026 Annual Meeting of Shareholders held on May 14, 2026. A significant portion of the issued and outstanding shares (87.78%) were present, establishing a quorum for Class A and Class B common stock combined. However, specific subclasses of Class B stock (B-1, B-2, B-3, and B-4) did not achieve the required 33.3% quorum, leading to the adjournment of proposals related to Items 4 through 8 to a new virtual meeting on June 9, 2026. Despite the adjournment of certain matters, the meeting did see voting on director elections, auditor ratification, and executive compensation. All director nominees were elected, the appointment of Ernst & Young LLP as the independent auditor was ratified, and the compensation of named executive officers was approved on an advisory basis. Investors should note the low participation from specific Class B shareholder groups, which necessitated the adjournment, and monitor the outcome of the rescheduled votes.
Key Highlights
- 1Annual Meeting held on May 14, 2026, with 87.78% of total outstanding shares represented, meeting the quorum requirement for combined Class A and Class B stock.
- 2Specific Class B shareholder subclasses (B-1, B-2, B-3, B-4) failed to achieve individual quorum requirements, necessitating adjournment of certain proposals.
- 3All nominated Equity Directors were elected to serve until the 2027 annual meeting.
- 4The appointment of Ernst & Young LLP as the independent auditor for 2026 was ratified.
- 5An advisory vote on the compensation of named executive officers was approved.
- 6Key proposals from Items 4 through 8 have been adjourned to a virtual meeting scheduled for June 9, 2026.